Last edition
News about "Oncology Drug"
Johnson & Johnson to Acquire Halda Therapeutics for USD 3.05 Billion
Johnson & Johnson has struck a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech company, for USD 3.05 billion in cash. Halda is known for its proprietary RIPTAC™ platform, which enables the development of oral, precision cancer therapies.
Oncology Drug | 18/11/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members